Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kinder Morgan Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Kinder Morgan Inc trades at $32.32 (market cap $71.46B). The key difference: Kinder Morgan Inc is the larger of the two by market cap, and Kinder Morgan Inc pays a 3.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KMI | |
|---|---|---|
Market Cap | $39.89B | $71.46B |
Sector | Health | Energy |
52-Week High | $491.22 | $34.31 |
52-Week Low | $278.09 | $25.84 |
Enterprise Value | $38.15B | $103.34B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Kinder Morgan (KMI) trades at $32.12, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $0.48 EPS, and maintains a solid dividend. Revenue grew to $16.94B in 2025, with net income margin improving to 18.92%. Recent news highlights KMI's exposure to natural gas infrastructure growth and stable cash flows from fee-based contracts.
KMI offers a balanced risk-reward profile with steady cash flow and dividend appeal, supported by a $10.1B project backlog. Risks include commodity price volatility and high debt levels. Analyst consensus is mixed but leans positive, with 47% buy ratings. The stock's valuation at a P/E of 21.56 is reasonable given earnings growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
